Denise Baez

Source: DGNews  |  Posted 1 week ago Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralisation By Denise Baez The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant appears to escape most therapeutic monoclonal antibodies and, to a large extent, vaccine-elicited antibodies, according to a study published in Nature.

By Denise Baez NEW YORK -- January 11, 2022 -- Among healthcare workers at a single centre in Israel who were previously vaccinated with a 2-dose series of the Pfizer-BioNTech BNT162b2 coronavirus disease 2019 (COVID-19) vaccine, administration of a booster dose, compared with not receiving one, was associated with a significantly lower rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection over a median of 39 days of follow-up, according to a study published in JAMA.

Source: DGNews  |  Posted 2 weeks ago Sotrovimab Reduces the Risk of Disease Progression in High-Risk Patients With Mild-to-Moderate COVID-19 By Denise Baez Sotrovimab, a pan-sarbecovirus monoclonal antibody, reduced the risk of disease progression in high-risk patients with mild-to-moderate coronavirus disease 2019 (COVID-19), according to interim findings from an ongoing study published in The New England Journal of Medicine.